COMMUNIQUÉS West-GlobeNewswire

Capital Increase in Genmab as a Result of Employee Warrant Exercise
16/06/2026
Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants. The increase is effected without [...]
Le KFSH met en avant une infrastructure d’innovation comme socle de la transformation évolutive des soins de santé au salon HLTH Europe 2026
16/06/2026
AMSTERDAM, 16 juin 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) profite de sa participation au HLTH Europe 2026, du 15 au 18 juin à Amsterdam, pour mettre en avant le fait que [...]
KFSH Highlights Innovation Infrastructure as the Foundation for Sustainable Healthcare Transformation at HLTH Europe 2026
16/06/2026
AMSTERDAM, June 16, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) is building on its participation at HLTH Europe 2026, taking place from June 15 to 18 in Amsterdam, to highlight [...]
UBC MOSAIC and LifeLabs Unlock New Ways to Manage and Predict Heart Health
16/06/2026
Toronto, Ontario, June 16, 2026 (GLOBE NEWSWIRE) -- The University of British Columbia MOSAIC research team and LifeLabs have partnered on an initiative that transforms how we understand and manage cardiovascular health [...]
FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
16/06/2026
Silver Spring, MD, June 16, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone [...]
Comprehensive Healthcare implements ZING® robot for methadone dosing
16/06/2026
Robotic methadone dosing assembly system allows for faster client service YAKIMA, Wash., June 16, 2026 (GLOBE NEWSWIRE) -- Comprehensive Healthcare has successfully implemented ZING®, a robotic methadone dosing assembly [...]
EssilorLuxottica et Applied Materials s’unissent pour faire progresser les dispositifs optiques de réalité augmentée destinés aux nouvelles générations de lunettes intelligentes
16/06/2026
EssilorLuxottica et Applied Materials s’unissent pour faire progresser les dispositifs optiques de réalité augmentée destinés aux nouvelles générations de lunettes intelligentes L'accord de développement conjoint vise à [...]
EssilorLuxottica and Applied Materials Join Forces to Advance Augmented Reality Optics Platforms for Next-Generation Smart Glasses
16/06/2026
EssilorLuxottica and Applied Materials Join Forces to Advance Augmented Reality Optics Platforms for Next-Generation Smart Glasses Joint development agreement aims to accelerate commercialization of next-generation [...]
Microbot Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations
16/06/2026
The agreement with Lovell Government Services creates opportunities to sell the LIBERTY® System at more than 2,000 government facilities, including those administered by the U.S. Department of Veterans Affairs, the [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
16/06/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 16 June 2026 at 16.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
16/06/2026
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are Younger than 10 [...]
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
16/06/2026
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which [...]
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
16/06/2026
Company continues to advance CYWC628 manufacturing with second GMP drug product run released for shipment to Australia and a third run nearing completion HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. ( [...]
CDT Equity Announces Debt Update and New Loan Facility
16/06/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has re-structured its debt, agreeing to pay off all [...]
NewGen Eliminates Convertible Note and Warrant Overhang with a Significant Investor, Enters Into Settlement Agreement Strengthening Capital Structure
16/06/2026
NewGen to repurchase all outstanding convertible notes and warrants previously held by a significant investor in move to strengthen its capital structure Settlement to eliminate potential dilution from convertible notes [...]
Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry
16/06/2026
Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings Company expects to complete the study by mid-July 2026, with [...]
GHK-Cu For Sale At Koi Peptides for Laboratory Use in 2026
16/06/2026
SHERIDAN, WY, June 16, 2026 (GLOBE NEWSWIRE) -- Koi Peptides has launched GHK-Cu, the copper tripeptide-1 complex that forms when copper(II) binds glycyl-L-histidyl-L-lysine (a tripeptide), as a research-use-only [...]
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
16/06/2026
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, [...]
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
16/06/2026
Accepted abstracts showcase Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life Data to be presented include 77.8% anxiety [...]

Pages